

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **PANGENOMIC HEALTH INC.** (the “Issuer”).

Trading Symbol: **NARA**

Number of Outstanding Listed Securities: **71,615,972 common shares**

Date: **September 2, 2022**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

PanGenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about

natural treatments. Our initial focus is on mental health. As a British Columbia benefit company, the Issuer's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

During the month of August 2022, the Issuer continued with its general and corporate activities of the business.

In addition, during the month of August 2022, management of the Issuer spent significant time preparing its condensed interim consolidated financial statements and management discussion and analysis for the six-month period ended June 30, 2022 (the "**Financial Report**").

2. **Provide a general overview and discussion of the activities of management.**

During the month of August 2022, the Issuer continued overseeing corporate activities.

During the month of August 2022, management of the Issuer spent significant time preparing its condensed interim consolidated financial statements and management discussion and analysis for the six-month period ended June 30, 2022 (the "**Financial Report**").

In addition, management of the Issuer negotiated a transaction with Mydecine Innovations Group Inc. ("**Mydecine**") and signed a non-binding letter of intent on August 31, 2022 whereby the Issuer will acquire all of the issued and outstanding shares of Mydecine's wholly-owned subsidiary, Mindleap Health Inc. ("**Mindleap**") (the "**Transaction**").

The LOI contemplates that the Company will acquire all of Mindleap's outstanding shares for a purchase price of C\$4,000,000 (the "Purchase Price"), payable by the issuance of units (each a "Unit") at an agreed-upon price of C\$0.20 per Unit (the "Unit Price"), or such higher price as the Canadian Securities Exchange (the "**CSE**") may require. Each Unit comprises one Class A Common Share of PanGenomic and one share purchase warrant (each a "**Unit Warrant**") to purchase one additional Share (a "**Unit Warrant Share**") for C\$0.30 per Unit Warrant Share, or such larger amount as the CSE may require, for 24 months from the closure ("Closing") of the purchase and sale of Mindleap Shares. In addition to the acquisition of Mindleap Shares at the Purchase Price, the Company and Mindleap will enter into a transition services agreement whereby the Company will engage Mindleap to assist in the transition, transfer, and integration of Mindleap technologies into PanGenomic's technology platform (the "Services") for two months following the Closing. In return for the Services, the Company shall pay a monthly consulting fee of \$50,000 (C\$100,000 total), payable at the Closing and on the one-month anniversary of the closing date.

On August 3, 2022 the Issuer announced by the way of news release that its Nara App is now available for download in North America on the Apple App Store and the Google Play Store. As one of Canada's first publicly-traded benefit companies, PanGenomic Health is committed to providing consumers with personalized information about evidence-based natural remedy solutions to support mental health.

"People are taking more control over their personal health decisions, and want access to evidence-based information about mental health solutions delivered in a consumer-friendly manner," said Robert Nygren, Executive Chair of PanGenomic Health. "With our Nara App, users can access, share and discuss trusted sources of information about treatments for mental health conditions in order to educate themselves about their own use of pharmaceutical and natural remedy medications."

In a widely reported study published last month in Molecular Psychiatry led by researchers from University College London, the UK, Italian and Swiss researchers carried out a systematic review of the evidence for the serotonin chemical imbalance theory of depression. The researchers concluded that "This review suggests that the huge research effort based on the serotonin hypothesis has not produced convincing evidence of a biochemical basis to depression. This is consistent with research on many other biological markers. We suggest it is time to acknowledge that the serotonin theory of depression is not empirically substantiated." [See: Moncrieff, J., Cooper, R.E., Stockmann, T. et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry (2022). <https://doi.org/10.1038/s41380-022-01661-0>]

The free Nara App includes a plant medicine library, curated articles, a mental wellness tracker, a community forum and access to DNA insight reports to learn how genetics may impact the effectiveness of natural remedy solutions.

The Issuer's aforementioned news release, news release on the Transaction and Financial Report can be viewed under the Issuer's profile on SEDAR (www.sedar.com). The Issuer's aforementioned news releases can also be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

During the month of August 2022, the Issuer's Nara App became available for download in North America on the Apple App Store and the Google Play Store.

See Item #2 for further details.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None to report during the month of August 2022.

5. **Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

During the month of August 2022, the Issuer entered into a Letter of Intent with Mydecine Innovations Group Inc. ("Mydecine"), to acquire all of the issued and outstanding shares of Mydecine's wholly-owned subsidiary, Mindleap Health Inc. ("Mindleap").

The transaction between the Issuer, Mydecine and its wholly-owned subsidiary Mindleap was negotiated by way of arm's length negotiations, as such, Mydecine and Mindleap are not considered to be related persons of the Issuer.

See Item #2 for further details.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None to report during the month of August 2022.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None to report during the month of August 2022.

8. **Describe the acquisition of new customers or loss of customers.**

None to report during the month of August 2022.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None to report during the month of August 2022.

10. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None to report during the month of August 2022.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

None to report during the month of August 2022.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None to report during the month of August 2022.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None to report during the month of August 2022.

14. **Provide details of any securities issued and options or warrants granted.**

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
No Securities Were Issued During the Month of August 2022.			

(1) State aggregate proceeds and intended allocation of proceeds.

15. **Provide details of any loans to or by Related Persons.**

None to report during the month of August 2022.

16. **Provide details of any changes in directors, officers or committee members.**

None to report during the month of August 2022.

17. **Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The trends and risks which are likely to impact the Issuer are detailed in the section named "Risk Factors" of the Issuer's Prospectus dated January 14, 2022, the Issuer Filing Statement dated July 13, 2022 and the Issuer's Management Discussion and Analysis dated May 20, 2022 (the "**MD&A**"), under the heading "Risk and Uncertainties". The Prospectus and Filing Statement can be viewed under the Issuer's Disclosure page on the website of the Canadian Securities Exchange. The MD&A can be viewed under the Issuer's profile on SEDAR (www.sedar.com).

THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 2, 2022

Vincent Lum
Name of Director or Senior
Officer

"Vincent Lum"
Signature
Chief Executive Officer
Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		Ended	YYYY / MM / DD
PANGENOMIC HEALTH INC.		August 2022	2022 / 09 / 02
Issuer Address			
Suite 102 – 3800 Wesbrook Mall			
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.	
Vancouver, BC V6S 2L9	N/A	778-743-4642	
Contact Name	Contact Position	Contact Telephone No.	
Vincent Lum	CEO	778-743-4642	
Contact Email Address	Web Site Address		
vincent@pangenomic.com	www.pangenomic.com		